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BACKGROUND: Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in
Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab
(in combination with interferon-a (IFN-a)) in the treatment of advanced metastatic RCC.
METHODS: Systematic literature searches were performed in six electronic databases. Bibliographies of included studies were searched
for further relevant studies. Individual conference proceedings were searched using their online interfaces. Studies were selected
according to the predefined criteria. All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating
advanced metastatic RCC in accordance with the European licensed indication were included. Study selection, data extraction,
validation and quality assessment were performed by two reviewers with disagreements being settled by discussion. The effects of
sunitinib and bevacizumab (in combination with IFN-a) on progression-free survival were compared indirectly using Bayesian Markov
Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.
RESULTS: Three studies were included. Median progression-free survival was significantly prolonged with both interventions (from
approximately 5 months to between 8 and 11 months) compared with IFN. Overall survival was also prolonged, compared with IFN,
although the published data are not fully mature. Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in
terms of progression-free survival (hazard ratios 0.796; 95% CI 0.63–1.0; P¼0.0272).
CONCLUSION: There is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically
relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC.
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For the past 20 years the mainstay of treatment for people with
advanced and metastatic renal cell carcinoma (RCC) has been
immunotherapy (interferon-a (IFN-a) and interleukin-2). This
treatment is frequently associated with unpleasant side effects and
confers only modest benefits. A recently updated Cochrane Review
identified 58 randomised clinical trials in which immunotherapies
had been used in advanced RCC. The weighted average median
survival was 3.8 months longer for IFN-a than for control
treatments (11.4 vs 7.6 months) (Coppin et al, 2005). Hormonal
treatments and standard chemotherapies are generally not
considered effective due to high levels of drug resistance (Fojo
et al, 1987; Mignogna et al, 2006). Improvements in drug treatment
for metastatic RCC have therefore been a priority for pharmaceu-
tical development, with several new-targeted agents recently
becoming available. In Europe, two agents are licensed for the
first-line use in metastatic RCC: sunitinib and bevacizumab
(in combination with IFN-a). Sunitinib is an oral multi-targeted
tyrosine kinase inhibitor that targets and blocks the signalling
pathways of multiple receptor tyrosine kinases. Bevacizumab is a
recombinant humanised monoclonal antibody, which inhibits
angiogenesis by preventing VEGF from binding to its receptors on
vascular endothelium and other vascular cells, inhibiting tumour
growth and proliferation. Both drugs have orphan drug status. The
aim of this review was to systematically review current evidence for
the effectiveness of sunitinib and bevacizumab. As both drugs
share a common indication, we considered it particularly
important to investigate the comparative effectiveness of sunitinib
and bevacizumab.
MATERIALS AND METHODS
Systematic literature searches were performed in August 2008 in
the following electronic databases: MEDLINE, Embase, Cochrane
Library (2008, Issue 3) (including CDSR, CENTRAL and HTA),
Science Citation Index Expanded and Web of Science Proceedings.
The search strategy included terms used to describe renal cancer
and the trade and proprietary names of the interventions and is
available in full on request from the authors. The search was
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slimited to original publications relating to humans. Bibliographies
of included studies were searched for further relevant studies.
Individual conference proceedings from the ASCO Annual Meeting
(2007 and 2008), ASCO Genitourinary Cancers Symposium (2007
and 2008) and ECCO (2007) were searched on their online
interface. All searches were re-run in November 2008 to identify
any additional publications.
Two reviewers (JTC and ZL) independently examined titles and
abstracts identified from the search and full texts of any potentially
relevant studies were obtained. The relevance of each paper was
then assessed independently according to the inclusion and exclu-
sion criteria and any discrepancies were resolved by discussion.
Randomised clinical trials were included if they compared either
sunitinib or bevacizumab in combination with IFN-a with
standard treatment (immunotherapy or best supportive care) as
first-line therapy (according to the European licensed indication)
in participants with advanced and/or metastatic RCC. Primary
outcomes were overall survival (OS) and progression-free survival
(PFS). We also considered the adverse events and toxicity reported
in the included trials. Only trials which reported at least one of the
primary outcomes were included in the review. Conference
abstracts were included if there was sufficient detail to assess
quality or if they reported updated results of included trials.
Data were extracted by one reviewer (ZL) using a standardised
data extraction form and checked independently by a second
(JTC). The methodological quality of the studies was assessed
using criteria specified by the Centre for Reviews and Disse-
mination (CRD).(NHS Centre for Reviews and Dissemi-
nation, 2001) Quality was assessed by one reviewer (ZL) and
judgments checked by a second (JTC). Any disagreement was
resolved by discussion, with involvement of a third reviewer (KS)
as necessary.
Details of the extracted data for each individual study are
presented in structured tables and as a narrative description.
Survival data (OS and PFS) are presented as hazard ratios (HRs)
where available.
As data on head-to-head comparisons between the interventions
were not available, we performed an indirect comparison
using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in
WinBUGS, with IFN as a common comparator (Ades, 2003),
adopting a fixed-effect model. This approach assumes ‘exchange-
ability’ of treatment effect across all included trials, such that the
observed treatment effect for any comparison could have been
expected to arise if it had been measured in the populations
reported in all other included trials. Exchangeability was judged
through examination of the trial populations and comparability of
outcomes in the common treatment group facilitating the
comparison.
Vague earlier distributions were used in the analyses (N[0,
0.001] for log-hazard ratios). Point estimates and 95% credible
intervals were calculated from 100000 simulated draws from the
posterior distribution after a burn-in of 10000 iterations. An
empirical P-value is also presented, simply calculated as the




After removal of duplicates, the initial search conducted in August
2008 generated 1087 references. One thousand and seventy three
papers were excluded on title and abstract. Full-text copies of the
remaining 14 citations was obtained and read in full. Six of these
citations were subsequently included in the review. The majority of
papers did not meet the exclusion criteria for multiple reasons;
only the first identified reason was recorded. Figure 1 shows details
of inclusion of papers in the systematic review.
Four additional conference abstracts were located as a result of
hand searching; one of these contained duplicate data. One
additional clinical trial was identified in the re-run search. A total
of 11 publications were therefore included in the review; these
relate to three clinical trials reported in the full-text publications
(Motzer et al, 2007b; Escudier et al, 2008; Rini et al, 2008) and
eight conference abstracts (Motzer et al, 2006, 2007a, 2007c;
Bracarda et al, 2007; Escudier et al, 2007; Melichar et al, 2007;
Bajetta et al, 2008; Figlin et al, 2008) relating to those trials.
Main search 
Titles and abstracts identified: 1087
Main search 
Full-text paper retrieved: 14
Included studies: 3 
Full-paper articles: 3 
Conference abstracts: 8 
Hand search 
Conference abstracts identified:  396 
Main search 
Trials excluded on title and extract: 
Publication type: 726
Study design: 37 
Population: 119 
Intervention: 179
Comparator: 3  
Outcomes: 9
Main search 
Trials excluded on full-text: 
Publication type: 3
Outcomes: 2
Duplicate conference abstract: 2
Duplicate full text: 1
Figure 1 Flow chart of trial selection process.
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sTwo included trials compared the effects of combination
treatment with bevacizumab (10mgkg
 1 body weight delivered
intravenously once every 2 weeks) plus IFN (nine MIU delivered
subcutaneously three times per week) compared with either IFN
plus placebo (AVOREN) (Escudier et al, 2008) or IFN alone
(CALGB) (Rini et al, 2008) on overall and PFS, and one trial
assessed the effect of sunitinib (50mg once daily; orally in 6-week
cycles – 4 weeks on and 2 weeks off) on the same outcomes
(Motzer et al, 2007b). Study characteristics are shown in Table 1.
Quality of evidence
All three included trials were large (4300 participants per arm),
phase III, international, multi-centre, randomised clinical studies.
Final OS results for the phase III trial of sunitinib vs IFN presented
at the ASCO Annual Meeting in 2008 include one post hoc analysis
of patients who did not receive any post-study treatment; only 47%
of the original study population is included. Demographic details
of the sub-group are not presented, hampering quality assessment
of this analysis.
Of the included trials, one (Escudier et al, 2008) was placebo
controlled and blinded, one trial (Motzer et al, 2007b) was not
blinded but an independent and blinded central review of images
was performed to assess PFS and objective response rate; the final
trial was not blinded and progression was assessed by the
investigator (Rini et al, 2008). All three studies were performed
in similar populations – predominantly clear cell, metastatic
RCC, the majority of patients having undergone nephrectomy
and having favourable or intermediate prognosis and good
performance status. All studies used explicit inclusion and
exclusion criteria and treatment groups were well matched at
study entry. None of the studies recruited patients with brain
metastases (unless neurologically stable) and relatively few
patients with bone metastases were included (20% in the AVOREN
trial and 30% in the trial of sunitinib vs IFN).
Assessment of OS
There was insufficient follow-up data to fully report median OS in
any of the trials, although subsequent conference presentations
have provided further details for the trial of sunitinib (Table 2)
(Motzer et al, 2007a, 2007b, 2007c; Figlin et al, 2008). In the
AVOREN trial, median OS in the IFN group was reported as 19.8
months and had not been reached in the bevacizumab group. The
researchers provided an estimated HR of 0.79 (95% CI 0.62–1.02;
P¼0.067). No further updated results have been published for this
trial. In the CALGB trial, no interim analyses of OS have yet been
performed.
Although at the time of reporting the original findings (Motzer
et al, 2007b) of the phase III trial of sunitinib vs IFN, median OS
had not been reached in either group; the authors provided an
estimated HR of 0.65 (95% CI 0.45–0.94; P¼0.02). This
comparison did not reach the pre-specified level of significance
for the interim analysis. Final OS data were reported at the ASCO
Annual Meeting in 2008 (Figlin et al, 2008). Material provided in
both the ASCO abstract and presentation slides provides three
analyses of OS from this study; an ITT analysis in which all
patients are included, an analysis in which data from 25 patients in
Table 1 Characteristics of included studies
Study AVOREN (Escudier et al, 2008; Bracarda
et al, 2007; Melichar et al, 2007; Escudier
et al, 2007; Bajetta et al, 2008)
CALGB (Rini et al, 2008) Motzer et al, 2006(Motzer et al, 2007b;
Motzer et al, 2007c; Figlin et al, 2008;
Motzer et al, 2007a; Motzer et al, 2006)
Design R, DB, PC, phase III, international, multi-
centre
R, phase III, international, multi-
centre
R, DB, PC, phase III international, multi-
centre
N 649 732 750
Diagnosis Metastatic, clear cell RCC Metastatic, clear cell RCC Metastatic, clear cell RCC
Prognosis profile according to
MSKCC criteria
27:56:9 (unavailable for 9% of patients) 26:64:10 38:56:6
(favourable: intermediate: poor)(%)
Patients having undergone previous
nephrectomy (%)
100 85 90
Intervention and comparator Bevacizumab plus IFN vs placebo plus IFN bevacizumab plus IFN vs IFN sunitinib vs IFN
Outcomes measured Overall survival*, progression-free survival,
overall response rate and safety
Overall survival*, progression-free
survival, objective response rate
and safety
Progression-free survival*, objective
response rate, overall survival, patient
reported outcomes and safety
Abbreviations: R¼ randomised; DB¼double blind; PC¼placebo controlled; RCC¼renal cell carcinoma; IFN¼interferon-a. *Primary outcome measure.
Table 2 Overall survival
Analysis Intervention N Median OS (months) 95% CI for median OS (months) HR 95% CI for HR P-value
AVOREN study (Escudier et al, 2008; Bracarda et al, 2007; Melichar et al, 2007; Escudier et al, 2007; Bajetta et al, 2008)
Interim Bevacizumab plus IFN 327 Not reached — 0.79 0.62–1.02 0.0670
Placebo plus IFN 322 19.8 — — — —
Sunitinib vs IFN phase III trial (Motzer et al, 2007b; Motzer et al, 2007c; Figlin et al, 2008; Motzer et al, 2007a; Motzer et al, 2006)
Second interim Sunitinib 375 Not reached — 0.65 0.45–0.94 0.02
IFN 375 Not reached —
Final Sunitinib 375 26.4 23.9–32.9 0.821 0.673–1.001 0.051
IFN 375 21.8 17.9–26.9
Censored final
a Sunitinib 375 26.4 23.0–32.9 0.808 0.661–0.987 0.0362
IFN 375 20.0 17.8–26.9
Post hoc final
b Sunitinib 193 28.1 19.5–NA 0.647 0.483–0.870 0.0033
IFN 162 14.1 9.7–21.1
Abbreviations: CI¼confidence interval; HR¼hazard ratio; IFN¼interferon; NA¼not applicable; OS¼overall survival.
an¼25 patients in the IFN group who crossed over to
sunitinib.
bIncludes only those patients who received no post-study treatment.
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sthe IFN group who crossed over to sunitinib within the study
protocol following disease progression are censored and finally a
post hoc analysis in which only those patients (n¼355; 47% of the
total study population) who received no additional treatment
following withdrawal from the study are included. All three sets of
results are presented in Table 2. Estimates of median OS in patients
treated with IFN range from 21.8 (95% CI 17.8–26.9) months in
the final analysis to 14.1 (95% CI 9.7–21.1) months in the post hoc
analysis. Estimates of median OS in patients treated with sunitinib
also vary according to the analysis undertaken, from 26.4 (95% CI
23.9–32.9) months and 26.4 (95% CI 23.0–32.9) months in the
final and censored analyses respectively to 28.1 (95% CI 19.5 to
NA) in the post hoc analysis. That people could expect greater OS
in an absence of the second-line therapy appears to be counter-
intuitive, as one would expect that the additional treatment
regimens would serve to prolong life. It is possible that this is a
spurious result as a consequence of the small number of people in
the analysis or the underlying reason for this group of people not
receiving the second-line therapy, it is possible that the group of
people who did not require additional treatment had a better
prognosis at the start of the study or perhaps it is a reflection of a
toxic effect of additional therapy. As these data are taken from a
conference abstract, full details of the analysis are not available.
Assessment of PFS
Although the method of assessment of progression varied between
the trials, all three showed an improvement in median PFS
compared with IFN (Table 3).
In both trials of treatment with bevacizumab plus IFN, median
PFS was significantly increased compared with IFN (either alone or
in combination with placebo), the effect being greater in the
AVOREN (10.2 vs 5.4 months; HR 0.63 95% CI 0.52–0.75;
Po0.0001) (Escudier et al, 2008) than the CALGB trial (8.5 vs
5.2 months; HR 0.71 95% CI 0.61–0.83) (Rini et al, 2008).
Treatment with sunitinib also improved median PFS compared
with IFN treatment in all available analyses. The most complete set
of data comes from an interim analysis performed in February
2007 (PFS data were not reported as part of the final analysis
presented in 2008). Results from the independent central review of
imaging studies showed a median PFS for patients treated with
sunitinib of 11 (95% CI 10.7–13.4) months and 5.1 (95% CI 3.9–
5.6) months for the IFN group, giving an HR of 0.538 (95% CI
0.439–0.658). Investigator-assessed results were similar at 10.8
(95% CI 10.6–12.6) months for sunitinib compared with 4.1 (95%
CI 3.8–5.3) months for IFN producing an HR of 0.519 ((95% CI
0.435–0.618).
Indirect comparison of the effects of sunitinib and bevacizumab
plus IFN As we identified no evidence of head-to-head compari-
sons of sunitinib and bevacizumab plus IFN, we assessed the
validity of performing an indirect comparison of the effects
of the two interventions on OS and PFS. Examination of the
key characteristics of the trials (Table 1) suggests that they are
suitably similar and indicates that an indirect comparison of
bevacizumab plus IFN vs sunitinib is appropriate. However, as
there is little mature OS data available and we were unable to
fully compare the trials in terms of the extent to which patients
received additional medications following withdrawal, we have
not performed an indirect comparison of the interventions in
terms of OS.
For the indirect comparison of PFS data, we chose to use the
most complete data from each trial (Table 4). The results of the
indirect comparison of PFS data suggest that over the length
of the assessment, people taking sunitinib were less likely to
progress than those taking bevacizumab plus IFN (P¼0.0272
(one-tailed test)). Sunitinib may therefore be superior to
bevacizumab plus IFN in preventing progression in this patient
population.
Table 3 Progression-free survival
Analysis Intervention N Median PFS (months)95% CI for median PFS (months) HR 95% CI for HR P-value
AVOREN study (Escudier et al, 2008; Bracarda et al, 2007; Melichar et al, 2007; Escudier et al, 2007; Bajetta et al, 2008)
Interim Bevacizumab plus IFN327 10.2 — 0.63 0.52–0.75 o0.0001
Placebo plus IFN 322 5.4 —
CALGB 90206 study (Rini et al, 2008)
Sixth interim
a Bevacizumab plus IFN369 8.5 7.5–9.7 0.71 0.61–0.83 o0.0001
IFN 363 5.2 3.1–5.6
Sunitinib vs IFN phase III trial (Motzer et al, 2007b; Motzer et al, 2007c; Figlin et al, 2008; Motzer et al, 2007a; Motzer et al, 2006)
Second interim Sunitinib 375 11
b 10–12 0.42 0.32–0.54 o0.001
IFN 375 5
b 4–6
Interim data cut-off February 2007Sunitinib 375 11




c Sunitinib 375 Not reported Not reported
IFN 375
Post hoc final
d Sunitinib 193 Not reported Not reported
IFN 162
Abbreviations: CI¼confidence interval; HR¼hazard ratio; IFN¼interferon; OS¼overall survival; PFS¼progression-free survival.
aEstimate of HR adjusted for stratification
factors – nephrectomy status and MSKCC risk factors.
bResults from independent review.
cn¼25 patients in the IFN group who crossed over to sunitinib.
dIncludes only those
patients who received no post-study treatment.
Table 4 Progression-free survival: indirect comparison of sunitinib vs bevacizumab plus IFN
Comparison Input data HR (95% CI) P-value
Sunitinib vs IFN Motzer: HR¼0.538; SE[ln(HR)]¼0.103 0.538 (0.439, 0.658) o0.0001*
Bevacizumab vs IFN {AVOREN: HR¼0.630; SE[ln(HR)]¼0.093 CALGB: HR¼0.710; SE[ln(HR)]¼0.079} 0.676 (0.601, 0.760) o0.0001*
Sunitinib vs bevacizumab [Indirect comparison] 0.796 (0.630, 1.004) 0.0272*
Abbreviations: HR¼hazard ratio; IFN¼interferon. Based on 100000 MCMC iterations.*One-tailed P-values.
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From the adverse events reported in these trials, the safety profile
of both interventions appears to be comparable with IFN, with
some adverse events particularly associated with bevacizumab plus
IFN (proteinuria, hypertension, bleeding events) and some with
sunitinib treatment (hypertension, hand and foot syndrome and
diarrhoea). The frequency of grade 3 or worse adverse events may
be higher with the combination of bevacizumab and IFN than with
IFN alone; in the CALGB trial 61% of people treated with IFN
reported grade 3 or 4 toxicity compared with 79% treated with the
combination of bevacizumab plus IFN (Po0.0001). During
treatment with sunitinib, there were significantly fewer grade 3
or worse adverse events reported than during treatment with IFN
(7 vs 12%; Po0.05).
DISCUSSION
Clinical data available from three randomised clinical trials
indicate that treatment with sunitinib and treatment with
bevacizumab (in combination with IFN) has clinically relevant
and statistically significant advantages over treatment with IFN
alone in terms of PFS. In the three included trials, median PFS was
significantly prolonged with the interventions, from around 5
months to 8.5 to 11 months compared with IFN. The reasons for
the slightly lower absolute value for PFS for bevacizumab plus IFN
in the CALGB trial are not clear but could be a result of small
differences in patient characteristics or differences in the
assessment of progression.
Both interventions also appear to have beneficial effects on OS
compared with IFN alone, but data are not fully mature from the
trials of bevacizumab plus IFN, and interpretation of the data from
the sunitinib trial is hampered by the lack of methodological detail.
All three trials were conducted predominantly in patients with
metastatic clear cell carcinoma with MSKCC risk factors suggestive
of a favourable or intermediate prognosis and who had undergone
a previous nephrectomy. Whether these results can be extrapolated
to other groups of patients with RCC (e.g., people diagnosed with
non-clear cell RCC or defined as having a poor prognosis
according to the MSKCC criteria) is unclear.
Data on adverse events suggest that sunitinib is not associated
with a greater frequency of adverse events than IFN alone,
although the adverse event profile is different and there is some
emerging concern about risk of cardiovascular events (European
Medicines Agency, 2008; Wu et al, 2008). There may be a higher
degree of toxicity associated with the combination of bevacizumab
and IFN compared with IFN alone.
As there is no head-to-head comparison data available for
bevacizumab plus IFN vs sunitinib, we performed an indirect
comparison which provides evidence that sunitinib may be more
efficacious than bevacizumab plus IFN in this patient group at
preventing progression. Findings here are consistent with a
recently published systematic review, which included an adjusted
comparison of the effects of treatment with sunitinib and
treatment with bevacizumab plus IFN on PFS, for metastatic
RCC. (Mills et al, 2009) Mills et al report sunitinib to be more
effective (HR 0.75, 95% CI 0.60–0.93, P¼0.001); however, the
researchers applied a fairly simple analytical approach. We chose
not to perform an indirect comparison of the interventions for OS
data due to the lack of mature OS data and the uncertainty
surrounding post-study medication use.
There is some debate within the clinical literature as to the
relative merits of OS and PFS, as primary end points in oncology
trials. It would be unethical to suggest that trial participants be
denied additional treatment once trial medication has failed or the
benefits of a treatment have been shown. However, the adminis-
tration of such treatment severely reduces the value of OS
estimates obtained from these trials. There may also be bias
associated with using PFS as a primary outcome due to the
subjective and intermittent nature of progression assessment.
Two of the trials included in this review used blinded central
review to assess progression, which may remove some of the
subjective measurement bias but may introduce complica-
tions related to timing of assessment and differences between
investigator and independent review. Little is known about the
relationship, if any, between PFS and OS in RCC, but it seems
likely that the new renal cancer drugs will provide some survival
gains.
Interferon was used as the comparator in all three trials. At the
time of trial design, IFN was considered the standard therapy for
advanced, metastatic RCC. However, the publication of the PERCY
Quattro (Negrier et al, 2007) trial of immunotherapy in patients
with intermediate prognosis suggested that IFN may show no
benefit in this patient group at the expense of a high frequency of
adverse events. Consequently, in some centres, people with
intermediate and poor prognosis are considered to be unsuitable
for treatment with IFN and best supportive care becomes their
only treatment option.
Using the MSKCC definition, approximately two-thirds of
patients (n¼650) in these three trials were considered to have
either intermediate or poor prognosis and could be considered,
using alternative definitions, to be unsuitable for treatment with
IFN. The extent to which the use of IFN as a treatment comparator
in patients who might not benefit from it has influenced the results
of these trials is unclear.
There are no published randomised clinical trials of the
effectiveness of treatment with sunitinib and treatment with
bevacizumab (in combination with IFN) compared with best
supportive care in patients who are unsuitable for treatment with
IFN. We considered the validity of performing an indirect
comparison between IFN and best supportive care to give a better
indication of the anticipated benefit of these interventions against
best supportive care. However, there are very few trials of IFN vs
best supportive care (which is variously defined) and those that
have been performed do not provide results according to
prognostic status. Informal extrapolation of available data suggests
that if it is assumed that there is no difference in the relative
effectiveness of best supportive care and IFN in this population,
even if one assumes a milder adverse event profile with best
supportive care, the new interventions should still be considered
effective.
In conclusion, there is evidence to suggest that treatment with
sunitinib and treatment with bevacizumab plus IFN has clinically
relevant and statistically significant advantages over treatment
with IFN alone in patients with metastatic RCC in terms of PFS.
Beneficial effects on OS have also been reported. In cases where
either treatment is considered an option, an indirect comparison
of available evidence suggests that treatment with sunitinib has
benefits in PFS over treatment with the combination of
bevacizumab and IFN.
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